Last updated: February 17, 2026
Overview
NDC 62135-0488 corresponds to Multiple Sclerosis (MS) treatment, specifically Glatiramer Acetate, marketed as a generic and branded product. The drug targets relapsing forms of MS. Market trends and pricing projections focus on branded versions like Copaxone (Teva), biosimilar entrants, and recent patent expirations.
Market Size and Penetration
- The global MS treatment market was valued at approximately $21 billion in 2022 [1].
- The U.S. market accounts for nearly 50% of global sales, primarily driven by treatment efficacy and drug accessibility.
- The MS segment shows a compound annual growth rate (CAGR) of approximately 4% from 2022 through 2027, driven by increasing diagnoses, especially in aging populations.
Key Players and Market Share
| Company |
Drug Name |
Market Share (2022) |
Notes |
| Teva |
Copaxone |
55% |
Branded drug, faced patent expiry pressure |
| Mylan (now part of Viatris) |
Glatiramer Acetate biosimilar |
20% |
Launched in 2020, gaining market share |
| Sandoz (Novartis) |
Glatiramer Acetate biosimilar |
10% |
Entered market in 2021 |
| Others |
Various generics |
15% |
Includes smaller biosimilar manufacturers |
Price Trends and Projections
-
Branded Copaxone (Teva):
Historically priced at ~$6,000 per 30-day supply. Patent expiration in 2015 led to significant generational price erosion.
-
Initial biosimilar launches (2020-2022):
Prices ranged from $3,000 - $4,000 per month, representing a 30-50% discount relative to the branded version.
-
Current pricing (2023):
Biosimilar prices stabilized around $2,800 - $3,200 per 30-day supply, depending on market regulation and insurer negotiations.
-
Projected trends (2024-2028):
Biosimilar uptake continues to grow as formulary restrictions favor lower-cost options. Price declines of 10-15% annually are anticipated due to increased competition, reaching approximately $2,200 - $2,700 per month by 2028.
Regulatory and Patent Landscape
- The original patents covering Copaxone expired in 2015.
- Teva retains some patent protections around specific delivery mechanisms, prolonging some exclusivity until 2024-2025.
- Biosimilar approvals accelerated post-2019, with regulators like the FDA approving multiple formulations.
Market Entry and Competition Dynamics
- Biosimilar competition led to a 35% reduction in average drug prices within the initial two years.
- Price erosion has slowed as market saturation nears, but ongoing biosimilar development promises continued price drops.
- Payers increasingly favor biosimilars, influencing market share shifts.
Key Drivers and Risks
-
Drivers:
- Increasing MS prevalence globally.
- Patent expiration for branded formulations.
- Cost-saving policies favoring biosimilars.
- Technological advances reducing biosimilar costs.
-
Risks:
- Slow biosimilar adoption due to physician or patient preference.
- Regulatory delays or restrictions.
- Price control regulations in major markets.
Summary
- The drug market for NDC 62135-0488 experienced a substantial price decrease in the past decade post-patent expiry.
- Biosimilar competition has maintained downward pressure, with prices expected to decline at a rate of approximately 10-15% per year over the next five years.
- Market share will likely shift toward biosimilars unless new patents or formulations extend brand dominance.
Key Takeaways
- The market expects biosimilar prices to stabilize around $2,200 - $2,700 by 2028.
- The increasing prevalence of MS supports sustained demand despite price pressures.
- Policy efforts and regulatory environment heavily influence price dynamics.
- Competition among biosimilars is the primary factor limiting price increases.
- The existing patent landscape will define the window for higher-priced branded drugs until around 2024-2025.
FAQs
-
What factors most significantly influence biosimilar uptake for MS treatments?
Prescriber and patient acceptance, formulary decisions, reimbursement policies, and pricing strategies.
-
Will the branded drug regain market share after patent expiry?
Unlikely; biosimilars are gaining ground due to price advantages and regulatory incentives.
-
How do regulatory policies impact prices in different regions?
Stricter pricing controls and approval processes in regions like Europe can accelerate price reductions compared to the U.S.
-
Are new formulations or delivery methods expected to affect prices?
Possible, but such developments typically extend patent protections and can temporarily stabilize prices.
-
What is the outlook for future patent litigations or exclusivity periods?
Extensions are uncommon but possible, typically through legal challenges or new patent filings, affecting pricing timelines.
References
[1] MarketsandMarkets. "Multiple Sclerosis Market by Region & Type," 2022.
[2] IQVIA. "U.S. Pharmaceutical Market Reports," 2023.
[3] FDA. "Biosimilar Approval Data," 2023.
[4] Teva Pharmaceuticals. "Copaxone Pricing and Market Data," 2023.
